Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament compound containing theophylines and statins

A composition and drug technology, applied in the field of medicine, can solve the problems of insignificant curative effect and large side effects, and achieve the effects of obvious curative effect, reduced side effects, and reduced drug side effects

Inactive Publication Date: 2010-09-08
NANTONG BOTAO CHEM
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In order to solve the shortcomings of insignificant curative effect and large side effects in the existing theophylline drugs in clinical treatment, the present invention provides a bronchial asthma treatment method with good curative effect, long action time and less side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament compound containing theophylines and statins
  • Medicament compound containing theophylines and statins
  • Medicament compound containing theophylines and statins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The preparation of embodiment 1 tablet

[0029] Pravastatin 6g

[0030] Aminophylline 150g

[0031] Microcrystalline Cellulose 200g

[0032] Sodium carboxymethyl starch 10g

[0033] Magnesium Stearate 4g

[0034] 8% starch slurry appropriate amount

[0035] Preparation process: Mix pravastatin, aminophylline and auxiliary materials microcrystalline cellulose and sodium carboxymethyl starch evenly, add appropriate amount of starch slurry to make soft material, and pass through a 16-mesh sieve to granulate. The wet granules are dried at 60°C, the dry granules are passed through a 16-mesh sieve for granulation, the fine powder in the dry granules is sifted out, mixed with magnesium stearate, and then mixed with the dry granules, and pressed into tablets to obtain the product.

Embodiment 2

[0036] The preparation of embodiment 2 tablet

[0037] Rosuvastatin 1.5g

[0038] Aminophylline 150g

[0039] Microcrystalline Cellulose 200g

[0040] Sodium carboxymethyl starch 10g

[0041] Magnesium Stearate 4g

[0042] 8% starch slurry appropriate amount

[0043] Preparation process: Mix pravastatin, aminophylline and auxiliary materials microcrystalline cellulose and sodium carboxymethyl starch evenly, add appropriate amount of starch slurry to make soft material, pass through a 16-mesh sieve to granulate. The wet granules are dried at 60°C, the dry granules are passed through a 16-mesh sieve for granulation, the fine powder in the dry granules is sifted out, mixed with magnesium stearate, and then mixed with the dry granules, and pressed into tablets to obtain the product.

Embodiment 3

[0044] The preparation of embodiment 3 tablet

[0045] Rosuvastatin 75g

[0046] Aminophylline 75g

[0047] Microcrystalline Cellulose 200g

[0048] Sodium carboxymethyl starch 10g

[0049] Magnesium Stearate 4g

[0050] 8% starch slurry appropriate amount

[0051] Preparation process: Mix pravastatin, aminophylline and auxiliary materials microcrystalline cellulose and sodium carboxymethyl starch evenly, add appropriate amount of starch slurry to make soft material, and pass through a 16-mesh sieve to granulate. Dry the wet granules at 60°C, pass the dry granules through a 16-mesh sieve for granulation, sieve out the fine powder in the dry granules, mix with magnesium stearate, and then mix with the dry granules, and press into tablets to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicament containing theophylines and statins. In the invention, the theophylines and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor form a compound to obtain excellent synergistic effect. The medicament compound greatly reduces the toxic and side effect of aminophylline when used alone, and the pharmacy security is improved.

Description

technical field [0001] The invention belongs to the technical field of medicine and specifically designs a new pharmaceutical composition for treating respiratory diseases. Background technique [0002] Asthma is a common respiratory disease, and its incidence is increasing year by year. The pathogenesis of asthma is very complex and has not been fully understood yet. In the 1950s, it was considered as an abnormal disease of airway smooth muscle function. In the early 1980s, it was proposed that the essence of asthma is airway hyperresponsiveness. Asthma is currently considered to be a chronic inflammatory disease of the airways involving a variety of cells and cellular components, characterized by reversible airflow obstruction in the lungs, airway mucosal inflammation, and airway hyperresponsiveness. [0003] Theophylline drugs have been used clinically as an anti-asthma drug for more than 60 years. With the continuous development of new anti-asthma drugs, the status of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/522A61K9/00A61P11/06A61K31/22A61K31/366A61K31/40A61K31/405A61K31/505
Inventor 齐云
Owner NANTONG BOTAO CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com